COVID-19

Moderna (MRNA) Beats Q3 on Sales of New COVID Shot, Trims 2025 Outlook; Stock Whipsaws — Nov. 6, 2025

Moderna, Inc. (NASDAQ: MRNA) posted third‑quarter 2025 revenue of ~$1.02 billion and a GAAP loss of $0.51 per share, topping Wall Street estimates as sales of its updated COVID‑19 vaccine outperformed. The company narrowed its full‑year revenue range to $1.6–$2.0 billion, cut operating‑expense guidance, and raised its year‑end cash outlook. Shares popped in pre‑market trading before wobbling intraday. SEC+1 What happened Moderna’s Q3 print outpaced expectations on both the top and bottom lines, led by stronger‑than‑modeled sales of its updated COVID‑19 shot (marketed this season as mNEXSPIKE/Spikevax 2025–26). Management simultaneously tightened the full‑year revenue band and lowered operating‑expense plans, signaling

6 November 2025

‘Hoarse Voice’ Could Be COVID: “Stratus” Variant Surges—Symptoms Doctors Flag, Where It’s Rising, and What Still Works

What is the “Stratus” COVID variant? “Stratus” is the colloquial name for XFG, a recombinant Omicron descendant (from LF.7 and LP.8.1.2). WHO added XFG to its monitoring list in late June and, based on available evidence, concluded the “additional public‑health risk … is low.” WHO’s lab summary notes spike‑protein changes (e.g., at positions 478 and 487) that can modestly increase immune escape compared with earlier JN.1‑family strains. World Health Organization Globally, XFG gained speed over the summer. WHO’s dashboard reports XFG was ~67% of submitted sequences in the week ending 31 Aug 2025; the runner‑up, NB.1.8.1 (“Nimbus”), accounted for ~21%.

28 September 2025

COVID-19 · Health News · Medical Advice · Symptoms · Virus Variants